Swedish Orphan Biovitrum (Sobi) is a Stockholm-listed specialist pharmaceutical company focused on rare and orphan diseases — haemophilia, immunology, oncology and specialty haematology. Operates in Portugal as Sobi Unipessoal Lda with its Lisbon office at Av. António Augusto de Aguiar 19, supplying treatments to the Portuguese hospital system.
Sobi’s Portuguese subsidiary — Sobi Unipessoal Lda — operates as the in-country commercial and regulatory presence for the group’s rare-disease portfolio. Its Lisbon office serves both as the marketing-authorisation holder for the Portuguese SNS (national health service) and as the field-medical hub interfacing with Portuguese haematology, immunology and rare-disease centres of reference at hospitals in Lisbon, Porto and Coimbra.
The Portuguese operation is structurally similar to Sobi’s footprint in Spain, France and Italy — a focused commercial team rather than a manufacturing site — and is part of the broader Nordic specialty-pharma pattern in Iberia, alongside Lundbeck (Denmark), Ferring (Switzerland-Sweden), LEO Pharma (Denmark) and Recipharm (Sweden).
Sobi’s presence is a quiet but durable example of Nordic specialty-pharma capital flowing into the Portuguese rare-disease market. As the Portuguese health system continues to add reimbursement coverage for advanced rare-disease therapies, Sobi’s Lisbon team is positioned as one of the cleaner channels through which Stockholm-headquartered orphan-drug capital reaches Portuguese patients.
Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.
Talk to Fractio →